Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease

Botey Katamu Benjamin, Wenjie Lu, Zhanying Han, Pan Liang, Xi Wang, Xiaofei Qin, Guoju Sun, Xule Wang, Yingguang Shan, Ran Li, Xiaolin Zheng, Wencai Zhang, Qiangwei Shi, Shuai Zhou, Sen Guo, Peng Qin, Chhatra Pratap Singh, Jianzeng Dong, Chunguang QiuJournal of Interventional Cardiology 2021 · DOI

TL;DR

This study investigates the effectiveness of drug-coated balloon (DCB) angioplasty as a sole treatment for narrowings in small coronary arteries, comparing outcomes between diabetic and non-diabetic patients. The findings suggest DCB-only treatment is effective, but diabetes remains a significant risk factor for complications, highlighting the need for tailored approaches in managing these patients.

What Problem Does This Paper Address?

Treating blockages in small coronary arteries (less than 2.75 mm in diameter) poses a significant challenge in cardiology. Traditional treatments like drug-eluting stents (DES) can lead to higher rates of stent failure and restenosis in these narrow vessels due to the presence of permanent metallic struts and the limited space for the vessel to adapt. Drug-coated balloons (DCBs) offer a promising alternative by delivering medication directly to the vessel wall without leaving a permanent implant. However, there's a lack of comparative data on DCB outcomes specifically in diabetic patients, who are known to have a higher prevalence of small vessel disease and poorer outcomes after interventions. This paper aims to fill that gap by comparing the one-year outcomes of DCB-only angioplasty in diabetic versus non-diabetic patients with de novo (new) lesions in small coronary vessels.

Methods

This was a prospective, single-center observational study involving 1198 patients undergoing percutaneous coronary intervention (PCI) for de novo lesions in small coronary vessels using a DCB-only strategy. Patients were categorized into diabetic and non-diabetic groups based on established diagnostic criteria. The primary endpoint was target lesion failure (TLF), a composite of ischemia-driven revascularization, target vessel myocardial infarction, or cardiac death. Secondary endpoints included major adverse cardiac events (MACE), defined as all-cause death, myocardial infarction, and target vessel revascularization. Clinical and angiographic follow-up was conducted at 12 months. Statistical analysis involved Fisher's exact test, chi-squared test, Student's t-test, and Cox proportional hazard multivariate analysis to identify independent predictors of TLF and target lesion revascularization (TLR).

Datasets

The study utilized data from 1198 patients treated at a single center between May 2015 and December 2020. This dataset was prospectively collected and included clinical, procedural, and 12-month follow-up data. No new benchmark datasets were introduced.

Key Insights and Ideas

  • DCB-only angioplasty is a viable option for small vessel disease: The study demonstrates that DCB-only treatment can achieve low rates of target lesion failure and major adverse cardiac events in small coronary vessels, suggesting it's a safe and effective alternative to stenting in this challenging subset of patients.
  • Diabetes significantly impacts outcomes: Despite the overall success of DCB-only treatment, diabetic patients experienced significantly higher rates of target lesion failure and target lesion revascularization. This underscores the persistent impact of diabetes on cardiovascular health and intervention outcomes, even with newer technologies.
  • Diabetes is an independent predictor of adverse events: The multivariate analysis confirmed that diabetes is an independent predictor of both target lesion failure and target lesion revascularization at one year, even after adjusting for other risk factors. This highlights the critical need for aggressive management of diabetes in patients undergoing PCI for small vessel disease.
  • No significant difference in MACE between groups: Interestingly, while TLF and TLR were higher in diabetics, the overall rate of major adverse cardiac events (MACE) did not reach statistical significance between the diabetic and non-diabetic groups at one year. This suggests that while specific components of MACE are affected by diabetes, the overall composite outcome might be less sensitive in this particular study.

Key Results

  • Target Lesion Failure (TLF): Significantly higher in the diabetic group (3.9%) compared to the non-diabetic group (1.4%) (P = 0.006).
  • Target Lesion Revascularization (TLR): Significantly higher in the diabetic group (2%) compared to the non-diabetic group (0.5%) (P = 0.014).
  • Diabetes as a Predictor: Diabetes was an independent predictor for TLF (HR: 2.712, CI: 1.254–5.864, P = 0.011) and TLR (HR: 3.698, CI: 1.112–12.298, P = 0.033) after adjustment.
  • MACE: While numerically higher in the diabetic group (4.4%) compared to the non-diabetic group (2.7%), this difference was not statistically significant (P = 0.120).
  • Angiographic Outcomes: Diabetic patients showed a trend towards higher late lumen loss (0.17 vs. 0.09 mm, P = 0.003) and binary restenosis (4.8% vs. 1.1%, P = 0.008).

Limitations and Future Work

The authors acknowledge several limitations:

  • Absence of angiographic follow-up for a significant number of patients: This could affect the assessment of long-term outcomes.
  • Short duration of follow-up: The 12-month follow-up may not fully capture long-term events.
  • Potential for overestimation of DCB performance: The small caliber of the treated vessels might have led to relatively weaker ischemic symptoms, potentially overestimating the performance of DCB.

Future research could focus on longer-term follow-up studies, larger multicenter trials, and investigations into specific strategies to mitigate the increased risk in diabetic patients undergoing DCB-only angioplasty for small vessel disease.

Summary updated

Abstract

Drug-coated balloon-only treatment achieved lower incidence rates of TLF and MACE. Diabetes is an independent predictor for target lesion failure and target lesion revascularization at one year following DCB treatment in small coronary vessels. We observed no significant differences between groups regarding MACE in one year.
BibTeX
@article{benjamin2021drug,
  author = {Botey Katamu Benjamin and Wenjie Lu and Zhanying Han and Pan Liang and Xi Wang and Xiaofei Qin and Guoju Sun and Xule Wang and Yingguang Shan and Ran Li and Xiaolin Zheng and Wencai Zhang and Qiangwei Shi and Shuai Zhou and Sen Guo and Peng Qin and Chhatra Pratap Singh and Jianzeng Dong and Chunguang Qiu},
  title = {{Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease}},
  journal = {Journal of Interventional Cardiology},
  year = {2021},
  doi = {10.1155/2021/2632343},
}
Figure